Skip to main content

Table 1 Demographics and Baseline Characteristics of Pediatric Patients Treated with Infliximab

From: Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis

Demographics and Clinical Characteristics

Number of patients (% of population)

Female, n = 27

18 (67%)

Race, n = 27

 Caucasian

22 (82%)

 African-American

2 (7%)

 Hispanic

2 (7%)

 Asian

1 (4%)

Juvenile idiopathic arthritis, n = 17

17 (63%)

 Extended Oligoarticular

3 (3 ANA+)

 RF-negative, Polyarticular

11 (9 ANA+)

 Enthesitis-related

1 (HLA-B27 +)

 Juvenile psoriatic arthritis

1 (ANA+)

 Undifferentiated

1 (ANA+)

Idiopathic

7 (26%)

Sarcoidosis

1 (4%)

HLA-B27-associated

1 (4%)

Other

1 (4%)

Serology, n = 27

 ANA positive

14 (52%)

 RF positive

0

 HLA-B27

1 (4%)

 HLA-B51a

1 (4%)

Uveitis Laterality, n = 27

 Bilateral

23 (85%)

 Unilateral

4 (15%)

Uveitis Location, n = 27

 Anterior

19 (70%)

 Intermediate

5 (19%)

 Anterior Intermediate

2 (7%)

 Panuveitis

1 (4%)

Age (Mos) of JIA Diagnosis (n = 17)

Ave ± SD (median)

43.6 ± 36.0 (23)

Age (Mos) of Uveitis Diagnosis (n = 27)

Ave ± SD (median)

86.5 ± 53.5 (76)

Duration of uveitis (Mos) prior to IFX start date, (n = 27) Ave ± SD (median)

39.6 ± 36.0 (22)

Follow-up Duration (Mos) on IFX, (n = 27) Ave ± SD (median)

41.6 ± 31.2 (35)

Previous Treatments prior to IFX Startb, n = 27

 Methotrexate (MTX)

21 (78%)

 Adalimumab (ADA)c

14 (52%)

 Etanercept (ETN)

1 (4%)

 Oral prednisone within 2 years prior to IFX start

7 (65%)

Indications for IFX

 Active uveitis in ≥1 eye pre-IFX [n = 27]

19 (70%)

 Active uveitis OR < 0.5+ cell, but > 2 drops PA 1% to control disease [n = 27]

24 (90%)

Active JIA (joint disease) [n = 17]

11 (65%)

  1. aNot routinely tested
  2. bNo patients were treated with cyclosporine or mycophenolate
  3. cAdalimumab was dosed at 20 mg every other week for patients 15 kg to < 30 kg and 40 mg for patients ≥30 kg. Three patients failed weekly weight-based therapy of adalimumab
  4. Abbreviations: Mos months, Ave average, SD standard deviation, PA 1% Prednisolone acetate 1%, MTX methotrexate, ADA adalimumab, IFX infliximab, RF rheumatoid factor, ANA+ anti-nuclear antibody positivity